We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of Direct Oral Anticoagulants for Acute Hospital Mortality in Venous Thromboembolism.
- Authors
Okushi, Yuichiro; Kusunose, Kenya; Nakai, Michikazu; Sumita, Yoko; Ise, Takayuki; Yamaguchi, Koji; Yagi, Shusuke; Fukuda, Daiju; Yamada, Hirotsugu; Soeki, Takeshi; Wakatsuki, Tetsuzo; Sata, Masataka
- Abstract
Background: The choice of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) is at the physician's discretion; however, it is useful to know the differences in the clinical data of DOACs to help physicians choose. Objective: We aimed to compare the mortality associated with the use of rivaroxaban, edoxaban, and apixaban in clinical practice. Methods: We identified 38,245 patients with first hospitalization for VTE from the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). We classified patients into three groups by DOAC (rivaroxaban and edoxaban group, rivaroxaban and apixaban group, and edoxaban and apixaban group) and compared the in-hospital mortality and bleeding risk by propensity score (PS) matching in each group. Results: After PS matching, patients with rivaroxaban use had significantly lower total in-hospital mortality (1.2% vs. 2.1%; odds ratio [OR] 0.55, p = 0.012) and in-hospital mortality within 21 days (0.4% vs. 1.0%; OR 0.41, p = 0.020) and 28 days (0.7% vs. 1.3%; OR 0.53, p = 0.042) than patients with apixaban use. In the subanalysis, significant differences were only observed in patients younger than 80 years of age, patients with pulmonary embolism, and patients without heart failure. There was no significant difference in in-hospital mortality in the other groups and in the rate of bleeding events among the three groups. Conclusion: On PS-matched analysis, there was a difference in in-hospital mortality, especially in the rivaroxaban and apixaban group. Identifying the clinical characteristics of patients associated with each DOAC, as well as prognosis, will be useful in determining treatment strategies for VTE.
- Subjects
HEMORRHAGE risk factors; VEINS; PULMONARY embolism; AGE distribution; ANTICOAGULANTS; HOSPITAL mortality; RIVAROXABAN; COMPARATIVE studies; THROMBOEMBOLISM; ODDS ratio; HEART failure
- Publication
American Journal of Cardiovascular Drugs, 2022, Vol 22, Issue 4, p407
- ISSN
1175-3277
- Publication type
Article
- DOI
10.1007/s40256-021-00514-5